Table 5.
Top 10 cited publications.
| Rank | Co-cited reference | Total Citations | Centrality | Year | Journal | IF (2022) | Corresponding author’s country |
|---|---|---|---|---|---|---|---|
| 1 | Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy | 237 | 0.04 | 2017 | Cell | 66.85 | China |
| 2 | Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries | 194 | 0 | 2018 | CA: A Cancer Journal for clinicians | 286.13 | USA |
| 3 | Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors | 188 | 0.02 | 2018 | Science | 63.714 | France |
| 4 | Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer | 180 | 0.03 | 2017 | Gut | 31.793 | China |
| 5 | The gut microbiota, bacterial metabolites and colorectal cancer | 174 | 0.04 | 2014 | Nature reviews mcrobiology | 78.297 | UK |
| 6 | Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment | 173 | 0.04 | 2013 | Cell host and microbe | 31.316 | USA |
| 7 | Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer | 172 | 0 | 2017 | Science | 63.714 | USA |
| 8 | Gut microbiome development along the colorectal adenoma-carcinoma sequence | 167 | 0.03 | 2015 | Nature communications | 17.694 | China |
| 9 | Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis | 163 | 0.04 | 2016 | Gut | 31.793 | USA |
| 10 | Gut microbiota imbalance and colorectal cancer | 160 | 0.03 | 2016 | World journal of gastroenterology | 5.374 | France |